Introduction: Extended survival outcomes from improved treatments for patients with cancer come with an increased risk for development of a metachronous second malignancy (MSM). We evaluated the incidence of MSM after successful treatment of SCLC and compared survival between patients with SCLC in whom MSM developed and those in whom it did not.
Introduction
Survival outcomes after treatment for many types of cancer have improved because of the ability to detect disease early and because of improvements in treatment modalities and supportive care. Extended survival outcomes after the treatment of a first cancer unfortunately come with an increased risk for development of a metachronous second malignancy (MSM) owing to environmental factors, cancer-specific treatments, or genetic predisposition. 1 SCLC is an aggressive form of lung cancer with notoriously poor survival, 2, 3 and overall survival (OS) rates have not improved substantially over the past 3 decades. 4, 5 Some patients in whom limited-stage SCLC (LS-SCLC) has been diagnosed have lived long enough to manifest MSM because of improvements in diagnostic imaging, radiation planning and delivery, and chemotherapy. 6 The survival rate for patients with LS-SCLC at 2 years has improved slightly from about 47% 7 to between 53% and 56% over the past 15 years, suggesting that patients with LS-SCLC, especially those whose disease responded well to treatment, should be monitored for the appearance of a second malignancy for a long time. However, because of the relative rarity of SCLC, the incidence of MSM after successful treatment is unknown.
In this study, we hypothesized that patients with LS-SCLC and development of MSM will survive longer than patients with no development of other malignancies or recurrent SCLC because the longer survival time after successful treatment of SCLC gives such patients more chance for development of MSM. Our primary objective was to evaluate the incidence and types of MSM that appeared after successful treatment of SCLC; our secondary objective was to compare survival between patients in who MSM developed and those in whom it did not.
Methods
We reviewed a large, single-institution database of patients with lung cancer to identify those who had received chemotherapy and radiotherapy (45 Gy) to the thorax for LS-SCLC from 1985 through 2012. MSM was defined as a second type of primary cancer appearing more than 2 years after the diagnosis of SCLC. 10 To avoid surveillance bias, we excluded patients in whom SCLC developed as MSM after treatment of other cancers, those in whom second malignancies developed within 2 years of the SCLC diagnosis, and those in whom nonmelanoma skin cancer developed as a second malignancy (Fig. 1) .
Diagnosis, treatment, and follow-up guidelines did not change appreciably over the course of the study, with the exceptions noted here. Routine use of positron emission tomography (PET) for disease staging began in 2000. Before 2000, thoracic radiation therapy was delivered either with two-dimensional anteroposterior/ posteroanterior fields followed by oblique fields or as nonconformal three-dimensional therapy; beginning in 2000, thoracic radiation was delivered as threedimensional conformal or intensity-modulated radiation therapy. Throughout the study period, the first follow-up visit took place 4 to 6 weeks after the completion of thoracic radiotherapy and included computed tomography (CT) of the chest and upper abdomen with and without contrast in addition to determination of complete blood count with differentials, blood urea nitrogen level, creatinine level, and electrolyte levels; liver function tests; and after 1998, PET-CT if the CT scans showed evidence of recurrence. After the completion of four cycles of etoposide with cisplatin or carboplatin, magnetic resonance images of the brain were obtained. Patients who at that time had a complete response or a good partial response were offered prophylactic cranial irradiation (25 Gy in 15 fractions). Thereafter, patients were followed up every 3 months for 2 years with CT scans, blood tests, and liver function tests; every 6 months for another 2 years; and then once a year indefinitely until death.
Statistical Analysis
Continuous variables were summarized by descriptive statistics such as means, standard deviations, medians, and ranges. Categorical variables were tabulated by frequency and percentage. OS was measured from the date of SCLC diagnosis until the date of death or last follow-up. OS was calculated by using Kaplan-Meier estimators, and the log-rank test was used to compare the Kaplan-Meier curves. Statistical significance was defined as a p value less than 0.05. Sex, age, year of diagnosis (2000 versus before 2000), race, smoking history and intensity, and treatment for SCLC (radiation dose, receipt and timing of chemotherapy [concurrent versus sequential or induction], and receipt of prophylactic cranial irradiation) were evaluated as potential predictors of MSM development by using Fisher's exact test and the Wilcoxon rank sum test.
Results
We identified 704 patients with LS-SCLC from 1985 through 2012. Of those 704 patients, we excluded 163 (32 for lack of follow-up information, 48 who had SCLC as MSM, 37 with nonmelanoma skin cancer as a second malignancy, and 46 with a second malignancy appearing either within 2 years before SCLC diagnosis [n ¼ 36] or within 2 years after SCLC diagnosis [n ¼ 10]). MSM developed in 15 of the 541 patients analyzed (2.8%); no second malignancy or recurrent SCLC developed in 180; and the remaining 346 had recurrent SCLC. The subjects of the current analysis were the first two groups, that is, those in whom MSM developed and those in whom it did not. (Fig. 1) . The median follow-up time was 91.4 months (range 38.3-207.7) for patients with MSM and 38.3 months (range 0.2-255.3) for patients with no other malignancies and no recurrence. Figure 2 shows survival curves for patients in whom MSM developed and those in whom a second malignancy or recurrent SCLC did not develop. The estimated OS rates were higher among patients in whom MSM developed than among patients in whom other malignancies did not develop, with 10-year rates of 61.9% (95% confidence interval [CI]: 30.0%-82.6%) and 29.9% (95% CI: 21.5%-38.6%), respectively (log-rank p ¼ 0.03).
Patient and treatment characteristics stratified by MSM or no MSM are shown in Table 1 . No differences between groups were found in any of the characteristics analyzed. Table 2 shows the characteristics of the 15 patients in whom MSM developed. The median time from the diagnosis of SCLC to the diagnosis of MSM was 91.4 months (range 35.6-157.3). The most common MSM histotypes were adenocarcinoma (n ¼ 8) and squamous cell carcinoma (n ¼ 5), followed by sarcoma (n ¼ 1) and acute myeloid leukemia (n ¼ 1); 13 of the 15 MSMs appeared in the lung. All 15 patients had achieved complete response after SCLC treatment. In the 15 patients with MSM, the MSM was acute myeloid leukemia in one and limited-stage cancer in the other 14. 
Discussion
Our major findings were that the incidence of MSM after treatment for LS-SCLC was 2.8% and that survival time after SCLC diagnosis, for patients with MSM, was sufficiently long to allow the development of MSM compared with patients who did not develop other malignancies or recurrent SCLC, as we had hypothesized. To the best of our knowledge, this is the first report on the incidence of MSM and survival for patients successfully treated for primary LS-SCLC. The rate of MSMs for all types of cancer in the U.S. population was approximately 0.56% in 2006, 11 indicating that the risk for MSM after treatment of LS-SCLC is higher. In 14 of the 15 patients in the current study in whom MSM developed, the MSM was detected at a limited stage and thus was potentially curable. Our findings suggest that early detection and treatment of MSM may be necessary to improve prognosis among long-term survivors of SCLC.
Another challenge is how to detect MSM after treatment of LS-SCLC. The National Lung Screening Trial showed that compared with using chest radiography for screening, using low-dose chest helical CT to screen people at high risk for development of lung cancer led to a 20% reduction in lung cancer deaths (95% CI: 6.8-26.7, p ¼ 0.004). 12 Moreover, the NELSON trial showed that even small nodules detected by screening had a high probability of being malignant. 13 Evaluation with PET can help to identify patients with low-risk, early-stage Hodgkin's lymphoma, who can be cured with less intensive treatment.
14 Screening guidelines recommend that asymptomatic cancer survivors at high risk for development of MSM be screened at the same intervals as those for screening the general population. 15 In the current study, in 13 of the 15 patients in whom MSM developed, the MSM developed in a lung, indicating that MSM after SCLC treatment can occur in a lung as a tumor of different histologic type, which is similar to the results reported in a review by Johnson more than 15 years ago. 10 Taken together, these results suggest that lowdose chest helical CT may be useful to screen for MSM among patients who received radiochemotherapy for SCLC.
Although some evidence exists to suggest that receipt of radiotherapy to the chest increases the risk for development of secondary lung cancer, 16, 17 whether reducing the radiation dose for SCLC would increase the risk for recurrence or reduce the risk for MSM remains unclear. The proven improvement in outcomes after concurrent radiotherapy led to its being established as standard therapy for LS-SCLC, 18 and a previous study by us indicated that completing thoracic radiotherapy within 6 weeks of concurrent chemotherapy led to improved survival outcomes. 19 Also, the type of chemotherapy and the radiation dose used for the initial treatment of SCLC in the current study did not seem to affect the incidence of MSM (p ¼ 0.84 and p ¼ 0.532, respectively). Thus at present, the therapeutic strategy need not change for patients with LS-SCLC who receive radiochemotherapy, but such patients should be followed carefully even after a good response to SCLC treatment.
Many patients with SCLC have a history of continuous smoking and correspondingly high smoking intensity (number of smoking pack-years), which might be expected to be correlated with the development of MSM, perhaps through affecting immune function and mutational burden. The number of pack-years of smoking and smoking status did not seem to affect the incidence of MSM in this study (p ¼ 0.21 and p ¼ 1.00, respectively). A recent review article considered cigarette smoking to be a "double-edged sword" in that it can both exacerbate pathologic immune responses and attenuate the normal defensive function of the immune system. 20 Previous studies have also shown an association between risk for development of a second cancer among survivors of SCLC and smoking, 21 and the high mutation burden associated with SCLC that may also be influenced by smoking. 22 Specifically, 75% to 90% of patients with SCLC have mutations in tumor protein p53 gene (TP53), [23] [24] [25] which often result in aggressive and highly complex disease presentations and may be conducive to the development of second malignancy regardless of previous therapies. The recent advent of immune checkpoint inhibitors has revolutionized cancer therapy, and the combination of immune checkpoint inhibitors and radiation therapy has shown some benefit in preclinical and clinical studies of other types of cancer. 26, 27 The programmed cell death 1 inhibitor pembrolizumab has had promising activity in patients with metastatic SCLC with high numbers of somatic mutations, suggesting that genomic alternations in SCLC may serve as potential therapeutic targets. 28, 29 Results of a phase I study investigating pembrolizumab with radiochemotherapy for LS-SCLC (NCT02402920) are expected to be available shortly. More comprehensive molecular analysis may be needed to further understand the factors associated with immunosuppression and mutation burden that may facilitate the development of MSM after LS-SCLC.
Our study had several limitations. First, the number of patients in whom MSM developed was small. Second, information on radiation fields and patients' genetic backgrounds and lifestyle factors such as alcohol or dietary consumption were not available for analysis but may have contributed to the risk for development of MSM.
1 Several genomic aberrations have been identified in SCLC, including retinoblastoma 1 gene (RB1), 22, 30, 31 TP53, [22] [23] [24] [25] and overexpression of poly (ADP)-ribose polymerase 1 gene (PARP). 32 Genomic analysis of patients in whom MSM develops may be helpful for developing more effective targeted treatment strategies. a Delivered as either two-dimensional anteroposterior/posteroanterior fields followed by oblique fields or nonconformal three-dimensional radiation therapy. b Delivered as three-dimensional conformal or intensity-modulated radiation therapy. MSM, metachronous second malignancy; pts, patients; chemo, chemotherapy; RT, radiation therapy; PCI, prophylactic cranial irradiation. In conclusion, we recommend that patients treated for LS-SCLC be made aware of the need for long-term follow-up and the importance of early detection and treatment of MSM. Despite many efforts to clarify the biology of SCLC and therapeutic strategies for it, therapeutic advances in SCLC have remained limited. 22 Smoking status, mutation status, and immune status all seem to be important in SCLC and may affect the choice of treatment for it, 33, 34 but whether these factors are associated with the development of second malignancies remains unknown at this time. Once effective treatment for LS-SCLC has been discovered, the risk for development of MSM will become still more important as the numbers of long-term survivors and their survival times increase after successful treatment of LS-SCLC. Further analysis is warranted to establish the optimal strategies for diagnosing or treating MSM in such cases.
